| HR | 95% CI | p |
---|---|---|---|
Univariate analysis: Covariate | |||
 Gender (female) | 0.68 | 0.44–1.06 | 0.092 |
 Age, years | 1.01 | 0.99–1.03 | 0.55 |
 Vascular endothelial growth factor, μg/L | 2.09 | 1.10–3.99 | 0.025 |
 Ctrough bevacizumab <15.5 mg/L | 2.34 | 1.52–3.58 | 9.9 × 10−5 |
 Log(carcinoembryonic antigen), μg/L | 1.21 | 1.10–1.34 | 9.8 × 10−5 |
 IL17A polymorphism (A carriers) | 0.86 | 0.56–1.30 | 0.47 |
 IL17F polymorphism (AG) | 1.80 | 0.87–3.73 | 0.11 |
 IL-1β, pg/mL | 1.23 | 0.69–2.21 | 0.48 |
 IL-4, pg/mL | 1.00 | 0.99–1.01 | 0.96 |
 IL-6, pg/mL | 1.00 | 0.99–1.00 | 0.49 |
 IL-10, pg/mL | 1.00 | 0.99–1.02 | 0.61 |
 IL-17A, pg/mL | 1.01 | 0.99–1.03 | 0.22 |
 IL-17F, pg/mL | 0.99 | 0.97–1.01 | 0.34 |
 IL-22, pg/mL | 1.07 | 0.99–1.15 | 0.057 |
 IL-31, pg/mL | 1.00 | 1.00–1.004 | 0.019 |
 IL-33, pg/mL | 1.00 | 0.99–1.00 | 0.95 |
 sCD40L, pg/mL | 1.00 | 0.86–1.06 | 0.83 |
 Tumor necrosis factorα, pg/mL | 0.97 | 0.86–1.09 | 0.61 |
Multivariate analysis: Covariate | |||
 Ctrough bevacizumab <15.5 mg/L | 1.88 | 1.19–2.97 | 0.0064 |
 Log(CEA), μg/L | 1.15 | 1.04–1.28 | 0.0057 |